Prof. Stephen L. CHAN
The Chinese University of Hong Kong, Hong Kong (China)
Email: L_chan@clo.cuhk.edu.hk
Qualifications
Ph.D., The Chinese University of Hong Kong
Publications (selected)
-
Chan SL, Mok T. PARP inhibition in breast and ovarian
cancers. Lancet. 2010; 376:211-213.
-
Chan SL, Mo F, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS,
Yeo W. New utility of an old marker: serial alpha-fetoprotein
measurement in predicting radiological response and survival of patients with
hepatocellular carcinoma undergoing systemic chemotherapy. J Clin
Oncol 2009; 27:446-452.
-
Wong VW*, Chan SL*, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, AT
Chan, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict
hepatocellular carcinoma in chronic hepatitis B carriers. (*equal
contribution). J Clin Oncol. 2010; 28:1660-1665.
-
Chan SL, Mo FK, Wong CS, Chan CM, Leung LK, Hui EP, Ma BB, Chan AT, Mok
TS, Yeo W. A study of circulating interleukin 10 in prognostication of
unresectable hepatocellular carcinoma. Cancer 2012.118:3984-9.
-
Chan SL, Mo FK, Wong VW, Liem GS, Wong GL, Chan VT, Poon MC, Loong HH, Yeo
W, Chan AT, Mok TS, Chan HL. Use of antiviral therapy in surveillance: impact
on outcome hepatitis B-related hepatocellular carcinoma. Liver
Internat. 2011; 32:271-8.
-
Chan SL. Commentary: the impact of compact lipiodolisation following
transarterial chemoembolisation for hepatocellular carcinoma. Aliment
Pharmacol Ther 2012; 36: 74-5.
-
Chan SL, Ma BB. Novel systemic therapeutic for nasopharyngeal
carcinoma. Expert Opin Ther Targets 2012;16 Suppl 1:S63-8.
-
Chan SL, Chan ATC, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma:
Prognostication, treatment monitoring or both. Future Oncol. 2009;
5:889-899.
-
Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BB, Leung TW,
Lai PB, Chan AT, Mok TS, Yeo W. Prospective validation of the Chinese
University Prognostic Index and comparison with other staging systems for
hepatocellular carcinoma in an Asian population. J Gastroenterol
Hepatol 2011;26:340-7.
-
Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and
future. J Gastroenterol Hepatol 2012;27:862-72.
-
Chan SL, Wong CH, Lau CPY, Zhou Q, Lui VWY, Ma BB, Chan AT, Yeo W.
Preclinical evaluation of combined TKI258 and RAD001 in hepatocellular
carcinoma. Cancer Chemo Pharma. Doi: 10.1007/s00280-013-2139-4
-
Chan SL, Mok T, Ma BB. Management of hepatocellular carcinoma: beyond
sorafenib. Curr Oncol Rep. 2012;14:257-66.
-
Ma BB, Chan SL. Hong Kong Cancer Institute/AACR International
Conference. Infection and cancer: biology, therapeutics and
prevention. IDrugs. 2009; 12:69-72.
-
Yeo W, Mo FK, Hui P, Chan SL. Need of stratifying patients according
to severity of underlying liver disease for hepatocellular carcinoma patients
undergoing systemic therapy trials. Contemp Clin Trials 2010;31:135.
-
Chan SL, Yeo W. Selecting the right patients for testing novel agents in
hepatocellular carcinoma: who, when and how? Asia Pac J Clin
Oncol 2013; 9:2-5.
-
Chan SL, Johnson P. Intra-arterial infusion of chemotherapy for advanced
hepatocellular carcinoma: an Asian perspective. Asia Pac J Clin
Oncol 2012;8:111-4.
-
Chan LC, Chiu SK, Chan SL. Stereotactic radiotherapy for
hepatocellular carcinoma: report of a local single-centre experience. Hong
Kong Med J 2011;17:112-118.
-
Ma BB, Chan SL, Ho WM, Lau W, Mo F, Hui EP, Chan C, Poon A, Dattatray
RD, Wong SC, King AD, Ahuja A, Chan AT. Intermittent versus continuous
erlotinib with concomitant modified "XELOX" (q3W) in first-line
treatment of metastatic colorectal cancer: Correlation With Serum Amphiregulin
and Transforming Growth Factor Alpha. Cancer, 2013;119:4145-53.
-
Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W,
Yu SC. Performance of serum α-fetoprotein levels in the diagnosis of
hepatocellular carcinoma in patients with a hepatic mass. HPB
(Oxford), doi: 10.1111/hpb.12146